Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CTCF_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CTCF_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CTCF_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CTCF_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CTCF_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CTCF_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000647913 | Oral cavity | EOLP | protein methylation | 35/2218 | 181/18723 | 2.30e-03 | 1.42e-02 | 35 |
GO:000821313 | Oral cavity | EOLP | protein alkylation | 35/2218 | 181/18723 | 2.30e-03 | 1.42e-02 | 35 |
GO:00063383 | Oral cavity | EOLP | chromatin remodeling | 46/2218 | 255/18723 | 2.34e-03 | 1.44e-02 | 46 |
GO:003506511 | Oral cavity | EOLP | regulation of histone acetylation | 14/2218 | 54/18723 | 3.37e-03 | 1.94e-02 | 14 |
GO:00008192 | Oral cavity | EOLP | sister chromatid segregation | 36/2218 | 202/18723 | 7.92e-03 | 3.76e-02 | 36 |
GO:001657013 | Prostate | Tumor | histone modification | 126/3246 | 463/18723 | 5.51e-08 | 1.65e-06 | 126 |
GO:003304414 | Prostate | Tumor | regulation of chromosome organization | 57/3246 | 187/18723 | 6.74e-06 | 1.02e-04 | 57 |
GO:001820512 | Prostate | Tumor | peptidyl-lysine modification | 99/3246 | 376/18723 | 6.77e-06 | 1.02e-04 | 99 |
GO:001839411 | Prostate | Tumor | peptidyl-lysine acetylation | 52/3246 | 169/18723 | 1.25e-05 | 1.76e-04 | 52 |
GO:000647311 | Prostate | Tumor | protein acetylation | 59/3246 | 201/18723 | 1.68e-05 | 2.25e-04 | 59 |
GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
GO:003105612 | Prostate | Tumor | regulation of histone modification | 46/3246 | 152/18723 | 6.07e-05 | 6.59e-04 | 46 |
GO:000647912 | Prostate | Tumor | protein methylation | 52/3246 | 181/18723 | 9.58e-05 | 9.35e-04 | 52 |
GO:000821312 | Prostate | Tumor | protein alkylation | 52/3246 | 181/18723 | 9.58e-05 | 9.35e-04 | 52 |
GO:190198311 | Prostate | Tumor | regulation of protein acetylation | 27/3246 | 77/18723 | 1.38e-04 | 1.27e-03 | 27 |
GO:200075611 | Prostate | Tumor | regulation of peptidyl-lysine acetylation | 23/3246 | 63/18723 | 2.14e-04 | 1.84e-03 | 23 |
GO:001657112 | Prostate | Tumor | histone methylation | 41/3246 | 141/18723 | 3.79e-04 | 2.95e-03 | 41 |
GO:004354311 | Prostate | Tumor | protein acylation | 63/3246 | 243/18723 | 4.64e-04 | 3.48e-03 | 63 |
GO:001657311 | Prostate | Tumor | histone acetylation | 43/3246 | 152/18723 | 5.27e-04 | 3.85e-03 | 43 |
GO:001839311 | Prostate | Tumor | internal peptidyl-lysine acetylation | 44/3246 | 158/18723 | 6.58e-04 | 4.66e-03 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTCF | SNV | Missense_Mutation | | c.2059G>A | p.Glu687Lys | p.E687K | P49711 | protein_coding | tolerated_low_confidence(0.46) | benign(0.001) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
CTCF | SNV | Missense_Mutation | | c.1132N>G | p.Pro378Ala | p.P378A | P49711 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
CTCF | SNV | Missense_Mutation | | c.850C>T | p.His284Tyr | p.H284Y | P49711 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-A8-A0AD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
CTCF | SNV | Missense_Mutation | | c.772N>G | p.Lys258Glu | p.K258E | P49711 | protein_coding | deleterious(0.05) | probably_damaging(0.971) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTCF | SNV | Missense_Mutation | | c.1327N>C | p.Asp443His | p.D443H | P49711 | protein_coding | tolerated(0.13) | probably_damaging(0.999) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
CTCF | SNV | Missense_Mutation | | c.850C>A | p.His284Asn | p.H284N | P49711 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-BH-A0DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
CTCF | SNV | Missense_Mutation | | c.1133N>T | p.Pro378Leu | p.P378L | P49711 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A0EA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | CR |
CTCF | SNV | Missense_Mutation | | c.847N>T | p.Arg283Cys | p.R283C | P49711 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0W4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTCF | SNV | Missense_Mutation | | c.851N>C | p.His284Pro | p.H284P | P49711 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0W5-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR |
CTCF | SNV | Missense_Mutation | rs746080386 | c.1327G>A | p.Asp443Asn | p.D443N | P49711 | protein_coding | tolerated(0.68) | probably_damaging(0.996) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |